This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is a Beat in Store for Alexion (ALXN) This Earnings Season?
by Zacks Equity Research
Alexion's (ALXN) blockbuster drug, Soliris, continues to perform well and the company is scheduled to report third-quarter 2017 results on Oct 26, before the opening bell.
Lilly (LLY) Beats on Q3 Earnings, Explores Sale of Elanco
by Zacks Equity Research
Eli Lilly (LLY) beat estimates for both sales and earnings in Q3 and upped its 2017 outlook. Separately, the company said that it is exploring strategic alternatives for the Elanco Animal Health business.
Eli Lilly (LLY) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
5 Toxic Stocks to Abandon or Sell Short for Gains
by Zacks Equity Research
Toxic stocks are susceptible to external shocks and are loaded with high amounts of debts. Also, the price of toxic stocks is irrationally high.
Agenus (AGEN) Remains Focused on Drug Development Programs
by Zacks Equity Research
Agenus' (AGEN) collaboration agreements provide a steady source of funds to boost pipeline development.
J&J's Arthritis Candidate Sirukumab Denied FDA Approval
by Zacks Equity Research
J&J (JNJ) said that the FDA has denied approval to its investigational rheumatoid arthritis treatment, sirukumab for want of additional safety data.
Zacks.com featured highlights: PTC, Apache, Incyte, Titan International and Carbonite
by Zacks Equity Research
Zacks.com featured highlights: PTC, Apache, Incyte, Titan International and Carbonite
5 Toxic Stocks to Discard or Sell Short for Profit
by Zacks Equity Research
Toxic stocks are exposed to outside shocks and are burdened with high levels of debts. Also, the price of toxic stocks is artificially inflated.
Lilly/Incyte's Baricitinib Meets Endpoint in Eczema Study
by Zacks Equity Research
Eli Lilly and Company (LLY) and partner Incyte announced that baricitinib met its primary endpoint in a phase II study in people with moderate-to-severe atopic dermatitis.
Incyte (INCY) Reports Positive Data on Epacadostat/Keytruda
by Zacks Equity Research
Incyte Corporation (INCY) announced new and updated data from the ongoing phase I/II ECHO-202 trial on pipeline candidate epacadostat with Keytruda.
Top Research Reports for Bank of America, Pepsi & American Express
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Bank of America (BAC), American Express (AXP), and Pepsi (PEP).
Lilly/Incyte to Re-File Baricitinib NDA Faster Than Expected
by Zacks Equity Research
Lilly (LLY) and Incyte announced that they will re-submit the new drug application (NDA) for their rheumatoid arthritis (RA) drug, baricitinib much faster than previously expected.
Incyte (INCY) Q2 Loss Wider than Expected, Jakafi Strong
by Zacks Equity Research
Incyte (INCY) reported a wider-than-expected loss in the second quarter but revenues beat expectations.
Key Takeaways from Lilly's (LLY) Q2 Call: Baricitinib, Cancer Pipeline
by Arpita Dutt
Why were Lilly's (LLY) shares down despite the company delivering a "beat and raise" quarter?
Biotech Stock Roundup: Amgen, Biogen Top Q2 Estimates, Update on Incyte RA Drug
by Arpita Dutt
Earnings season kicked off on a positive note for biotech stocks with big players like Amgen (AMGN) and Biogen reporting better than expected results.
Lilly (LLY) Q2 Earnings Top, Baricitinib Re-Filing Delayed
by Zacks Equity Research
Eli Lilly and Company (LLY) beat estimates for both sales and earnings in Q2 and upped its 2017 outlook. However, it said the NDA resubmission for baricitinib will not occur this year, which hurt shares.
Incyte & Lilly's Olumiant Gets Marketing Approval in Japan
by Zacks Equity Research
Incyte Corporation (INCY) and partner Eli Lilly and Company (LLY) announced that arthritis drug Olumiant got approval in Japan.
Aduro Starts Phase II Combo Study with CRS-207 & Keytruda
by Zacks Equity Research
Aduro Biotech, Inc. (ADRO) has announced initiation of a phase II study to evaluate a combination therapy of its lead candidate, CRS-207, in combination with Keytruda, for treatment of patients with pleural mesothelioma (MPM).
Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca
by Zacks Equity Research
Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca
Better Days Ahead for the Pharma Sector?
by Arpita Dutt
Sales, R&D, strong results, and a higher number of FDA approvals.
Stocks to Fight Cancer: Why Immunotherapy Is a Gamechanger
by Eric Dutram
This podcast takes a closer look at the world of cancer research, and in particular, that of immunotherapy. I have guest Brad Loncar on to discuss this market and a few promising candidates to watch in this area, check it out for more info on this interesting biotech segment!
Incyte (INCY) Up 3.4% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Incyte Provides Updated Data on Cancer Combination Therapies
by Zacks Equity Research
Incyte along with partner Bristol-Myers Squibb announced updated data from phase I/II study, ECHO-204, evaluating epacadostat in combination with Opdivo for the treatment of squamous cell carcinoma of the head and neck and melanoma.
Incyte Announces Data on Enzyme Inhibitor with Keytruda
by Zacks Equity Research
Incyte Corporation (INCY) and Merck & Co. (MRK) announced an updated data from the advanced non-small cell lung cancer patient cohort of the ongoing phase I/II ECHO-202 study.
Company News for May 19, 2017
by Zacks Equity Research
Companies in the News are: LB,P,INCY,MRK,SHPG